At a Walgreens in San Francisco's Japantown, a pharmacist keeps two boxes of long-acting insulin pens bearing the California grizzly bear, the label of CalRx, the state's own prescription drug brand. She has not dispensed a single one. She keeps them in stock, she told KFF Health News, in case someone comes in without insurance, or for an emergency.

That small scene contains the whole puzzle. California spent years and tens of millions of dollars to put an affordable insulin on pharmacy shelves, and it succeeded: CalRx insulin glargine pens launched on January 1 at $55 for a five-pack, roughly $11 a pen, against cash prices that had run past $500. The product exists, it is priced as promised, and it is interchangeable with a widely used brand, so no new prescription is needed. And it is barely moving. Understanding why is more interesting than either the celebration or the criticism the program usually attracts, because the obstacle is not the one the program was designed to remove.

Almost nobody pays the price CalRx undercuts

The program's premise was that insulin costs too much, which was true and, for many people, catastrophically so. But the number CalRx attacks is the cash or list price, and the great majority of patients never pay it. Insured patients pay a copay set by their plan. What they encounter at the counter is not a price but a benefit design, and a cheaper product on the shelf does not change what their plan charges them.

This is the gap between making a drug affordable and making it reach people. CalRx solved the price. The barrier is the machinery that stands between a price and a patient: what the insurer covers, what the pharmacy benefit manager places on formulary, what the pharmacy stocks and offers, and what the prescriber writes. That machinery is largely indifferent to whether a cheaper product exists, and in some ways it is worse than indifferent.

California's own copay cap competes with California's insulin

There is a genuine irony sitting inside the state's own policy portfolio. Alongside CalRx, California enacted a law capping insured patients' insulin cost-sharing at $35 for a monthly supply. That cap is a real benefit to a large number of people, and it is hard to argue against.

It also means that for most insured Californians, the state's $55 cash-price product is not the cheapest option available to them. Their copay is lower. So one state policy substantially reduces the demand for another state policy, and the population for whom CalRx is the best deal shrinks to those the copay cap does not reach. This is not a scandal or an error; both measures address real problems and both help real people. But it explains a great deal about why boxes sit unopened, and it is the kind of interaction that gets lost when each initiative is announced on its own terms.

The distribution system is built to disfavor cheap drugs

Now the deeper mechanism, and the one with implications far beyond insulin. In the American drug supply chain, many of the intermediaries earn money in proportion to price, or from the spread between a list price and a negotiated net price. Pharmacy benefit managers negotiate rebates off list prices, and formulary placement follows those rebates. Wholesalers and pharmacies earn margin that is often a function of the price of what passes through them.

Consider what that means for a product priced at $45 to the pharmacy and capped at $55 to the patient. The pharmacy's gross margin is about ten dollars a pack, thin in dollar terms compared with what a high-list product can generate. There is no rebate for a PBM to collect, because there is no inflated list price to discount from. There is no coupon program, no enrollment, no spread. Civica has said plainly that this is the point, that the price is stable and transparent with no rebates or coupons required, and for a patient that simplicity is a real virtue.

But the same transparency that makes the product good for patients makes it unattractive to the intermediaries who decide what gets stocked, listed, and dispensed. The cheap product is structurally disadvantaged precisely because it is cheap. That is the generalizable lesson here: in a market where the middle of the chain is paid from price, lowering the price removes the incentive to carry your product. Making something cheaper does not automatically make it reach people, and it can make distribution harder rather than easier.

What CalRx is actually good for

None of this means the program is pointless, and it is worth being precise about who it genuinely serves, because the pharmacist's instinct was right. For someone with no insurance, a stable $55 price at the counter is transformative compared with a cash price several times higher. For someone in a high-deductible plan who has not yet met the deductible, it can beat what their insurance would charge. And for anyone who has tried and failed to navigate manufacturer discount programs, which require enrollment, eligibility, and renewal, an unconditional shelf price that requires nothing of you is worth more than its dollar figure suggests.

That last point deserves weight. Complexity is itself a barrier, and a price that requires no application, no coupon, and no proof of anything is accessible in a way that a nominally lower but conditional price is not. So CalRx is not useless. It is aimed at a smaller and more specific population than the headline framing implied, and its distinguishing feature is arguably not that it is cheap but that it is simple and unconditional.

The market already moved, partly because of pressure like this

Here is the reading that neither the program's boosters nor its critics tend to offer. Part of the reason CalRx is selling slowly is that the problem it was designed to solve has genuinely eased. The three dominant insulin makers cut their list prices sharply, by roughly 65% to 80%, and introduced out-of-pocket caps of their own. Combined with federal and state cost-sharing caps, the affordability gap that existed when California announced this effort in 2023 is considerably narrower now.

And those price cuts did not arrive spontaneously. They followed years of political pressure, litigation, public outrage, and the credible threat of exactly this kind of public competition. Which means slow CalRx sales may partly measure the success of the broader pressure campaign rather than the failure of the product. A state that sets out to discipline a market and finds the market has disciplined itself has not obviously lost. It has arrived to find the fight partly won, which looks identical, on a sales report, to having built something nobody wanted.

The deterrent that disappears if it works

That points to the genuine difficulty ahead, and it is a structural one rather than a partisan one. If a public option's main value is as a standing threat, holding down what incumbents dare charge, then success shows up as low sales rather than high ones. The program works by existing, not by selling. But a program with few sales is politically fragile, easy to characterize as a costly failure, and an obvious target when budgets tighten. California has already eliminated the $50 million it had set aside for an in-state insulin manufacturing facility as a budget savings measure.

The trap is plain. Cancel the deterrent because it deters, and the discipline it imposed on prices goes with it, at which point prices are free to drift back up, and the whole cycle can begin again. Sustaining something whose value is invisible, and whose success is measured in prices that never rose rather than units that sold, is not a thing governments do well. Whether the state should be in the drug business at all is a real policy dispute on which reasonable people disagree, and this analysis takes no side in it. But the case for CalRx, if there is one, has to be argued on this ground, in terms of prices restrained rather than boxes moved, and that is a harder case to make to a legislature than a sales figure would be.

So the pharmacist with two undispensed boxes is not evidence of a program that failed, and not evidence of one that succeeded either. She is evidence that price and access are different problems, and that California solved the first while the second is controlled by insurance design, formulary placement, and a distribution chain whose economics quietly punish inexpensive products. That is worth understanding for its own sake, because it applies well beyond insulin: any effort to make something cheaper has to reckon with whether the people who decide what reaches the shelf have any reason to carry it. For Californians without insurance, or stranded in a deductible, or worn down by coupon programs, those two boxes are a genuine and unconditional option that did not exist eighteen months ago, and that matters for a medicine people have rationed at real cost to their health. Whether the program endures long enough to keep mattering will depend on whether anyone can explain why a product that barely sells might be doing its job.

Primary sources

  1. STAT, co-publishing KFF Health News reporting by Angela Hart, for the account of a San Francisco pharmacist stocking but not dispensing CalRx insulin pens and keeping them on hand for uninsured patients or emergencies, and for the finding that California's state-branded insulin has been slow to reach patients while still holding potential to reshape the market.
  2. California CalRx program materials and the Governor's office, for the January 1, 2026 launch of CalRx biosimilar insulin glargine pens at a maximum of $55 per five-pack, about $11 per pen, the white-label partnership between nonprofit manufacturer Civica Rx and Biocon Biologics, the product's interchangeability with Lantus, the comparison with prior cash prices of roughly $300 per vial or more than $500 per five-pack, and the elimination of the $50 million allocated for an in-state manufacturing facility as a budget savings measure.
  3. CalMatters and other coverage for Newsom's statements, the three-year gap between announcement and availability, Civica's nationwide distribution of the same product at the same price, Civica spokesperson Liz Power's point that the price involves no rebates, coupons, or enrollment programs, and the roughly 65% to 80% list-price cuts by Eli Lilly, Novo Nordisk, and Sanofi and their patient discount programs.
  4. Reporting on California Senate Bill 40, capping insured patients' insulin cost-sharing at $35 per monthly supply, and Senate Bill 41, addressing pharmacy benefit managers.